Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
Abstract Background Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer’s disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with spor...
Main Authors: | Carla M. Startin, Nicholas J. Ashton, Sarah Hamburg, Rosalyn Hithersay, Frances K. Wiseman, Kin Y. Mok, John Hardy, Alberto Lleó, Simon Lovestone, Lucilla Parnetti, Henrik Zetterberg, Abdul Hye, LonDownS Consortium, André Strydom |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-019-0477-0 |
Similar Items
-
Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome
by: Carla M. Startin, et al.
Published: (2019-04-01) -
Comparison of Receptive Verbal Abilities Assessed Using the KBIT-2 and BPVS3 in Adults With Down Syndrome
by: Carla M. Startin, et al.
Published: (2019-01-01) -
Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
by: Andre Strydom, et al.
Published: (2018-04-01) -
Health comorbidities and cognitive abilities across the lifespan in Down syndrome
by: Carla M. Startin, et al.
Published: (2020-01-01) -
The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer’s Disease in Down Syndrome
by: Sarah E. Pape, et al.
Published: (2021-04-01)